Key Developments: Ibio Inc (IBIO.A)
0.42USD
24 May 2013
$-0.02 (-3.78%)
$0.44
$0.45
$0.45
$0.41
10,800
16,973
$1.70
$0.36
Latest Key Developments (Source: Significant Developments)
iBio Inc Closes $4.2 Million Public Offering
iBio Inc announced that it has closed an underwritten public offering of 8,925,000 shares of the Company's common stock and warrants to purchase 3,570,000 shares of the Company's common stock. The securities were sold as a unit with each unit consisting of one share of common stock and 4/10ths of a warrant to purchase one share of common stock. The public offering price of each unit was $.48 resulting in gross proceeds of approximately $4,284,000 before underwriting discounts and other expenses. iBio plans to use proceeds of the offering for working capital, including further development of iBio's product candidates and technology, business development and for other general corporate purposes. Roth Capital Partners acted as sole manager for the offering. Full Article
iBio Inc Announces Proposed Public Offering
iBio Inc announced that it is offering shares of its common stock and common stock purchase warrants in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners, LLC is acting as the sole manager for the offering. iBio plans to use proceeds of the offering for working capital, including further development of iBio's product candidates and proprietary technology, business development and for other general corporate purposes. Full Article
iBio Inc Announces CFO Change-Form 8-K
iBio Inc reported in its Form 8-K that effective February 21, 2013, the Board of Directors of the iBio, Inc. (Company) appointed Scott Kain, to serve as Chief Financial Officer (CFO) of the Company; Douglas Beck, his predecessor as Chief Financial Officer (CFO), became a senior adviser. Full Article
iBio Inc and Caliber Biotherapeutics LLC Establish License And Collaboration Relationship
iBio Inc and Caliber Biotherapeutics LLC (Caliber) announced execution of a License and Collaboration Agreement for development and production of recombinant plant-based biopharmaceuticals using iBio's iBioLaunch technology and Caliber's and plant-based manufacturing capabilities. Full Article
National Institute of Health Awards Contract to Support Use of iBio Inc's Technology for Improved Anthrax Vaccine
iBio Inc announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a contract to the Company's research and development collaborator, the Fraunhofer USA Center for Molecular Biotechnology, for a new generation anthrax vaccine to be developed with the iBioLaunch Platform under a research license from iBio. The first year of funding will be $1.76 million with a total contract amount of up to $9.9 million, depending on the exercise of contract options. Full Article
iBio Inc And General Electric Co's GE Healthcare Form New Global Alliance
iBio Inc and GE Healthcare, the healthcare business of General Electric Co announced a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines. The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio's plant-based vaccine manufacturing platform, iBioLaunch, with GE Healthcare's capabilities in technologies for biopharmaceutical manufacturing. iBio's research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB) will continue to play a key role in advancing the iBioLaunch platform. Financial terms were not disclosed. Full Article
iBio Inc Announces Further Positive Results With iBioModulator Platform
iBio Inc announced further positive results in ongoing tests demonstrating that its immunomodulator molecule, lichenase (LicKM), enhances the performance of vaccine antigens when produced as fusions to LicKM. iBio indicated it will offer commercial collaborations and product licenses to this immunomodulator under the trade name iBioModulator. An immunomodulator is a substance that alters the immune response. Animal studies have shown that the iBioModulator platform can increase the strength of the immune response specific to a vaccine antigen (as measured by antibody titer). Commercial applications of this platform include the development of more effective vaccines. Among the data confirming the performance of iBioModulator technology are results on the immunogenicity of an iBioModulator-based transmission-blocking malaria vaccine candidate produced with the Company's iBioLaunch protein expression platform. Data show that use of iBioModulator results in vaccine antigens with greater ability to stimulate a specific antibody responses (Human Vaccines 7:1 Supplement, 1-2; January 2011). Extended studies to evaluate the prolonged protective effect of lichenase-fused vaccine antigens for PFs25 and other malaria antigens are underway, and new data will be discussed as they become available. Full Article
iBio Inc Announces Successful Completion Of H1N1 Influenza Vaccine Phase 1 Clinical Trial
iBio Inc announced completion of the first human trial of iBioLaunch-produced H1N1 influenza vaccine (HAC1) that began September 13, 2010. This Phase 1, single-blind, placebo-controlled, dose-escalation study was conducted to assess the safety and reactogenicity and immunogenicity of HAC1 produced by iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology. Safety and reactogenicity assessments were completed at WRAIR-CTC and immunogenicity evaluation was performed by the Influenza Division of the Centers for Disease Control and Prevention. The final analyses confirm the results of the June 2, 2011, announcement of the safety and immunogenicity of the HAC1 vaccine which was found to be safe and well tolerated at all dose levels, with or without adjuvant. There were no reported serious adverse events or dose-limiting toxicities. No subjects withdrew from the study as a consequence of an adverse event. The analyses also showed that the HAC1 vaccine elicited high levels of immune responses which correlated directly with the amount of antigen administered when the vaccine was not adjuvanted. The immune response was the highest in subjects who received the non-adjuvanted highest HAC1 dose which was comparable with the immune response of the licensed, control H1N1 vaccine. Full Article
iBio Inc Prices $10 Million Public Offering
iBio Inc announced the pricing of an underwritten public offering of 15,385,000 units at $0.65 per unit for gross proceeds of approximately $10 million. Each unit consists of one share of common stock and 0.75 of a warrant to purchase one share of common stock. The warrants will have an exercise price of $0.88 per share, will be exercisable beginning one year and one day from the date of issuance, and will expire on the first anniversary of the date they first become exercisable. The offering is being made pursuant to an effective registration statement under the Securities Act of 1933, as amended. iBio plans to use proceeds of the offering for operating costs, including continuing to develop applications of its proprietary technology, business development and for other general corporate purposes. Roth Capital Partners is acting as sole manager for the offering. iBio expects to close the transaction, subject to customary conditions, on or about January 13, 2012. Full Article
iBio Inc Announces Proposed Public Offering
iBio Inc announced that it intends to offer shares of its common stock and common stock purchase warrants in an underwritten public offering. Roth Capital Partners, LLC is acting as the sole manager for the offering. iBio plans to use proceeds of the offering for operating costs, including continuing to develop applications of proprietary technology, business development and for other general corporate purposes. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
